Itoco

Dorzolamide Hydrochloride, the active ingredient in Itoco, is a carbonic anhydrase inhibitor presented as an ophthalmic solution for ocular use. It reduces the production of aqueous humor, thereby lowering intra‑ocular pressure in patients with glaucoma or ocular hypertension. The medication is administered as eye drops and is indicated for chronic management of elevated intra‑ocular pressure to prevent optic nerve damage.

GNH USA supplies Itoco as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Dorzolamide Hydrochloride is used to manage conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: lowers intra‑ocular pressure to help preserve visual field. Ocular hypertension: reduces aqueous humor production to maintain normal pressure. Secondary glaucoma (e.g., steroid‑induced): assists in controlling pressure when other causes are present.

Adverse reactions may occur with ocular administration of Dorzolamide Hydrochloride.

Common Side Effects: - Transient eye burning or stinging after instillation. - Blurred vision or temporary visual disturbance. - Altered taste sensation when the solution drains into the throat. - Conjunctival hyperemia (eye redness).

Serious or Rare Side Effects: - Severe allergic reaction including angio‑edema or anaphylaxis. - Corneal edema or keratitis leading to visual impairment. - Persistent intra‑ocular inflammation that may threaten vision.

Before prescribing Dorzolamide Hydrochloride, clinicians should consider several safety aspects.

Assess intra‑ocular pressure regularly: ensure therapeutic effect and adjust therapy as needed. Avoid use in patients with sulfonamide hypersensitivity: consider alternative agents. Do not instill while wearing contact lenses: remove lenses before dosing and wait before reinserting. Monitor for systemic carbonic anhydrase inhibition: watch for signs of metabolic acidosis in susceptible patients. Store at room temperature: keep in the original container, protect from light and moisture.

Dorzolamide Hydrochloride may interact with other medications affecting ocular pressure or systemic carbonic anhydrase activity.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive IOP‑lowering effect and risk of metabolic acidosis. - Topical beta‑blockers combined with other IOP‑lowering agents: may cause excessive hypotony.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: can increase IOP, requiring closer pressure monitoring. - Systemic sulfonamides: potential cross‑reactivity in sulfonamide‑allergic patients. - Anticholinergic eye drops: may alter tear film and affect drug absorption.